Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome



Status:Completed
Conditions:Women's Studies, Endocrine
Therapuetic Areas:Endocrinology, Reproductive
Healthy:No
Age Range:18 - 40
Updated:4/21/2016
Start Date:November 2010
End Date:September 2014

Use our guide to learn which trials are right for you!

The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome

The purpose of this study is to study the effect of a commonly used antibiotic, doxycycline,
on the production of ovarian hormones and menstrual cycles in women with Polycystic Ovarian
Syndrome (PCOS).

Polycystic ovarian syndrome (PCOS) is one of the leading causes of female infertility,
affecting 5-10% of reproductive-age women . This heterogeneous disorder is characterized by
anovulatory infertility, androgen excess, an increase in the ratio of LH to FSH, and
morphologic polycystic changes to the ovaries. Obesity and insulin resistance are also
metabolic factors associated with PCOS that further increase the morbidity in these
patients. Inducing fertility in patients with PCOS can be a challenge, as it most often
involves ovulation induction that can lead to ovarian enlargement, hyperstimulation, and
multiple-birth pregnancies. This study is designed to determine novel effective strategies
to promote normal cycling in this patient population.

Inclusion Criteria:

1. Women between 18 and 40 years of age.

2. History of PCOS with < 8 periods the proceeding year

3. Clinical or biochemical evidence of androgen excess

4. BMI <40

5. Willingness to sign consent for study including participation with collection of
blood specimens

6. Willingness to discontinue OCP for duration of study period up to 36 weeks

Exclusion Criteria:

1. Pregnancy

2. Hypersensitivity to doxycycline or tetracycline

3. History of Cushing's syndrome

4. History of hyperprolactinemia

5. History of congenital adrenal hyperplasia

6. Significant hepatic impairment, including serum AST or ALT >1.5 times upper limits of
normal.

7. Significant renal impairment, GFR <60 ml/min

8. Current use of metformin, statins, glucocorticoids, spironolactone and/or
anti-estrogens.
We found this trial at
1
site
?
mi
from
Rochester, NY
Click here to add this to my saved trials